Floatz logo

Daunorubicin

Acute Myeloid Leukemia

Shen yangPhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
59/ 100

Competitive context

684 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB
Posaconazole
AstraZeneca
Phase 4BBB

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →